Introduction: Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. is the core of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma 600196.SH; holding parent company Fosun International 0656.HK) in the pharmaceutical industry The holding company is a platform for industry investment, mergers and acquisitions in the field of pharmaceutical manufacturing and sales. The company focuses on the research and development, production and sales of diabetes, cardiovascular and tumor treatment drugs. It is the largest animal-derived insulin manufacturer in China. The field of diabetes treatment is the main competitor of multinational companies. At present, the domestic market share of insulin series products extracted from animal sources is more than 80%. The products include diabetes treatment drugs (insulin series preparations and oral hypoglycemic drugs), cardiovascular products, tumor products and other traditional Chinese medicine series. Multiple products occupy dominant positions in market segments. The company has R&D, BD departments, and experienced R&D teams with PhDs and masters. It acquires new products from domestic and foreign countries through development, introduction, and cooperation. Currently, many varieties are in clinical trials and preparation for launch. The company has a strong technical force in the field of process quality, including the introduction of technical management talents from abroad, and is currently making every effort to promote the construction and certification of cGMP production bases.
The company currently controls 6 corporate entities (Jiangsu Wanbang Pharmaceutical Marketing Co., Ltd., Shanghai Kaimao Biopharmaceutical Co., Ltd., Shanghai Zhaohui Pharmaceutical Co., Ltd., Hebei Wanbang Fulin Pharmaceutical Co., Ltd., Xuzhou Wanbang Jinqiao Pharmaceutical Ltd., etc.). The affiliated marketing company has a professional marketing team of more than 1,000 people, including six business departments and marketing departments such as prescription drugs, traditional Chinese medicine, and business. It has a relatively mature information platform and management support systems such as finance and HR, sales management, training and performance The management platform has been continuously optimized and improved, and the sales area covers all provinces and autonomous regions except Tibet; Wanbang Pharmaceutical's sales revenue exceeded 1.2 billion yuan in 2012. Sales revenue in 2013 is expected to be 1.5-2 billion yuan.
The company has a history of 30 years and is committed to becoming a well-known enterprise in the field of diabetes treatment in the world. It is currently developing rapidly through both endogenous and external methods, and continues to improve its marketing capabilities and R&D capabilities to form core competitive advantages. Fosun Pharma relies on its international resources and management, technology platform development, introduction of patented innovative drugs and high-value Generic drugs focus on the endocrine metabolism and cardiovascular fields as the market core, and at the same time gradually enter the anti-tumor field to enhance product strength. Wanbang Pharmaceutical has been advocating the corporate culture of "troops, schools, families" for more than ten years, creating an environment for learning and growth, promoting the concept of equality and harmony, and advocating execution and high-performance work culture. We believe that talents and these talents-related cultures and philosophy are fundamental to supporting the long-term development of an enterprise.
Our vision is to be the best pharmaceutical company in China with a professional attitude and entrepreneurial spirit. This is a challenging task and mission. We sincerely look forward to the joining of outstanding talents at home and abroad.
Legal representative: Wu Yifang
Date of establishment: 1998-12-30
Registered capital: RMB 440.4554 million
Region : Jiangsu Province
Unified Social Credit Code: 91320300714139872F
Business status: In business
Industry: Manufacturing
Company type: Limited liability company
English name: Jiangsu Wanbang Biopharmaceutical Co Ltd
Staff size: 1000-4999 people
Company address: Jinshanqiao Development Zone, Xuzhou City, Jiangsu Province South side of Dongshan Comprehensive Area
Business scope: Production and sales of freeze-dried powder injections, small-volume injections, tablets, capsules, biological products, APIs, Class II electrochemical analysis instruments, injection puncture instruments, Sales of needle-free injection instruments, Category III insulin syringes, insulin injection pens, low-temperature insulin carrying bags, and diagnostic test strips; retail of packaged foods and health foods (limited to branch operations). Self-operated and agent import and export business of various commodities and technologies. *(Projects that require approval according to law can only be carried out with approval from relevant departments)